Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.71 |
| ▸ | MMP8 | P22894 | 2/20 | 0.71 |
| ▸ | MMP13 | P45452 | 2/20 | 0.71 |
| ▸ | MMP2 | P08253 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | YAP1 | P46937 | 1/20 | 0.53 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.53 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730849 | 1.00 | ADAM17 (0.71) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL12730569 | 1.00 | ADAM17 (0.71) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL8324207 | 0.90 | GAA (0.68) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL19214946 | 0.86 | KMT2A (0.68) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL8207825 | 0.86 | ADAM17 (0.67) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL6323346 | 0.86 | ADAM17 (0.67) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL12730547 | 0.85 | KMT2A (0.64) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL8329165 | 0.83 | ADAM17 (1.00) | ADAM17MMP8MMP13MMP2 | |
| SCHEMBL12730568 | 0.83 | ADAM17 (0.52) | ADAM17MMP8MMP13MMP2PKM | |
| SCHEMBL12708189 | 0.83 | ADAM17 (1.00) | ADAM17MMP8MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919520-B2 | Inhibitors of tace | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090176782-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7485664-B2 | Inhibitors of TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2004056766-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176782-A1 | INHIBITORS OF TACE | HDGF, ADAM17, PCSK9 | ADAM17 2/4885MMP8 44/4885MMP13 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.